Acurx announces first patient enrolled in phase 2b clinical trial of its lead antibiotic for treatment of clostridioides difficile infection (cdi)

Staten island, n.y. , dec. 6, 2021 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the first patient has been enrolled in its phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat cdi, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022.
ACXP Ratings Summary
ACXP Quant Ranking